Biogen: Analysts’ Recommendations on October 19

Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. The adjusted EPS is estimated to be $6.78 in the third quarter—compared to the adjusted EPS of $6.31 in the third quarter of 2017.

The above chart shows analysts’ recommendations for Biogen stock over the last 12 months.

Biogen’s stock price has decreased nearly 4.1% in the last 12 months. So far, the stock price has increased ~3.6% in 2018. Analysts’ estimates show that the stock could return ~18.4% over the next 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

As of October 19, there are 29 analysts tracking Biogen. Eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold” for Biogen. None of the analysts recommended a “sell” for Biogen stock. The changes in analysts’ estimates and recommendations are based on the changing trends in the stock price and the company’s performance.

The consensus rating for Biogen stands at 2.03, which represents a “buy” for long-term growth investors and value investors.

As of October 19, Biogen is trading at a forward PE multiple of 12.2x—compared to the industry average of 14.3x. The company is trading at a forward EV-to-EBITDA multiple of 9.0x—compared to the industry average of 12.4x. Biogen is trading at a forward EV-to-revenues multiple of 5.1x—compared to the industry average of 4.7x.

Notably, the VanEck Vectors Biotech ETF (BBH) holds 5.0% of its total investments in Biogen, 7.1% in Gilead Sciences (GILD), 4.9% in Celgene (CELG), and 4.9% in BioMarin Pharmaceuticals (BMRN).